Salts and polymorphs of tetracycline compound

Stable crystalline and polymorphic forms of tetracycline compounds, particularly the tosylate salt, address stability issues, enhancing bioavailability and safety by ensuring consistent therapeutic levels and compliance with regulatory standards.

JP2024169444AInactive Publication Date: 2024-12-05PARATEK PHARMACEUTICALS INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2024157101
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2008-05-23
Filing Date
2024-09-11
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Tetracycline compounds exhibit stability issues in their solid phase due to polymorphic forms, leading to potential fatal overdoses and regulatory challenges, necessitating the development of stable crystalline and polymorphic forms for improved bioavailability and safety.

Method used

The development of stable crystalline forms, such as the tosylate salt of tetracycline compounds, including polymorphs with specific X-ray diffraction peaks, is achieved through controlled crystallization processes using solvents like isopropanol and p-toluenesulfonic acid, ensuring purity and stability.

Benefits of technology

The stable crystalline and polymorphic forms of tetracycline compounds provide enhanced stability, bioavailability, and safety, reducing the risk of overdoses and regulatory compliance by maintaining consistent therapeutic levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169444000023
    Figure 2024169444000023
  • Figure 2024169444000024
    Figure 2024169444000024
  • Figure 2024169444000025
    Figure 2024169444000025
Patent Text Reader

Abstract

To provide crystalline forms, including salts and polymorphs, of tetracycline compounds useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms.SOLUTION: The invention provides an aminoalkyl tetracycline compound represented by formula (1), tosylate salts of the compound, and methods of preparing the stable crystalline tosylate salts.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of priority under 35 U.S.C. 119(e) to co-pending U.S. Provisional Patent Application No. 61 / 128,712, filed May 23, 2008, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] 2. Background of the Invention The development of tetracycline antibiotics was a direct result of the systematic screening of soil samples collected from many parts of the world for evidence of microorganisms capable of producing bactericidal and / or bacteriostatic compositions. The first of these new compounds was introduced in 1948 under the name chlortetracycline; two years later, oxytetracycline became available. Elucidation of the chemical structures of these compounds confirmed their similarity and provided the analytical basis for producing the third member of this group, tetracycline, in 1952. A new family of tetracycline compounds lacking the ring-attached methyl group present in earlier tetracyclines was prepared in 1957 and became commercially available in 1967; minocycline came into use in 1972.

[0003] In recent years, research efforts have been focused on developing new tetracycline antibiotic compositions that are effective in various therapeutic conditions and routes of administration. New tetracycline analogues are also being investigated, and they may prove to be equal to or more effective than the originally introduced tetracycline compounds. Examples include U.S. Patent Nos. 2,980,584 (Patent Document 1); 2,990,331 (Patent Document 2); 3,062,717 (Patent Document 3); 3,165,531 (Patent Document 4); 3,454,697 (Patent Document 5); 3,557,280 (Patent Document 6); 3,674,859 (Patent Document 7); 3,957,980 (Patent Document 8); 4,018,889 (Patent Document 9); 4,024,272 (Patent Document 10); and 4,126,680 (Patent Document 11). These patents are representative of the range of pharma- ceutical active tetracycline and tetracycline analog compositions.

[0004] Historically, shortly after its initial development and introduction, tetracyclines were found to be highly pharmacologically effective against rickettsiae; numerous gram-positive and gram-negative bacteria; and the causative agents of venereal lymphogranulomatosis, inclusion conjunctivitis, and psittacosis. Thus, tetracyclines became known as "broad-spectrum" antibiotics. With their in vitro antibacterial activity, efficacy in experimental infections, and pharmacological properties subsequently established, tetracyclines as a class rapidly became widely used for therapeutic purposes. However, the widespread use of tetracyclines for both major and minor illnesses and diseases directly led to the emergence of resistance to these antibiotics, even in highly susceptible bacterial species, both commensal and pathogenic (e.g., pneumococci and Salmonella). The emergence of tetracycline-resistant organisms has generally led to a decline in the use of tetracyclines and tetracycline analog compositions as antibiotics of choice.

[0005] Each pharmaceutical compound has optimal therapeutic and lethal blood concentrations. The bioavailability of a compound determines the strength of the dosage in the drug formulation required to obtain the ideal blood level. If a drug can crystallize as two or more polymorphs with different bioavailability, the optimal dose will depend on the polymorphs present in the formulation. Some drugs exhibit a narrow range between therapeutic and lethal concentrations. For example, chloramphenicol-3-palmitate (CAPP) is a broad-spectrum antibiotic known to crystallize in at least three polymorphic forms and one amorphous form. The most stable form, A, is commercially available. The difference in biological activity between this polymorph and another stable form, B, is eight-fold, thus creating the possibility of a lethal overdose of the compound if it is unintentionally administered as form B due to changes during processing and / or storage. Thus, regulatory agencies such as the U.S. Food and Drug Administration have begun to exercise strict control over the polymorph content of active ingredients in solid dosage forms. Generally, for drugs that exist in polymorphic forms, regulatory authorities may require batch-by-batch monitoring if material other than the pure, thermodynamically preferred polymorph is marketed. Thus, it is important for both medical and commercial reasons to produce and sell a pure drug in its most thermodynamically stable polymorphic form, substantially free of other kinetically preferred polymorphs.

[0006] For example, salt forms of a compound, and polymorphic forms of the free compound or salts, are known in the pharmaceutical arts to affect, for example, the solubility, dissolution rate, bioavailability, chemical and physical stability, flowability, fractability, and compressibility, as well as the safety and efficacy of drugs based on the compound (see, e.g., Knapman, Modern Drug Discovery, 2000, 3(2): 53).

[0007] Thus, identifying a salt form or free base of a compound with optimal physical and chemical properties would advance the development of a tetracycline compound as a drug, the most useful of which include the following: easy and reproducible preparation, crystalline, non-hygroscopic, water soluble, stable to visible and ultraviolet light, low decomposition rate under accelerated stability conditions of temperature and humidity, low rate of isomerization between isomeric forms, and safety when administered long term to humans. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] U.S. Patent No. 2,980,584 [Patent Document 2] No. 2,990,331 [Patent Document 3] No. 3,062,717 [Patent Document 4] No. 3,165,531 [Patent Document 5] No. 3,454,697 [Patent Document 6] No. 3,557,280 [Patent Document 7] No. 3,674,859 [Patent Document 8] No. 3,957,980 [Patent Document 9] No. 4,018,889 [Patent Document 10] No. 4,024,272 [Patent Document 11] No. 4,126,680 [Non-patent literature]

[0009] [Non-Patent Document 1] Knapman, Modern Drug Discovery, 2000, 3(2): 53 Summary of the Invention

[0010] In one embodiment, the present invention provides, at least in part, an aminoalkyl tetracycline compound, Compound 1: TIFF2024169444000001.tif27128 relates to stable solid state forms, including crystalline forms, of (4S,4AS,5AR,12AS)-4-7-bis(dimethylamino)-9{[(2,2-dimethylpropyl)amino]methyl}-3,10,12,12A-tetrahydroxy-1,11-dioxo-1,4,4A,5,5A,6,11,12A-octahydrotetracene-2-carboxamide (9-(2,2-dimethyl-propyl-aminomethyl)-minocycline).

[0011] In another embodiment, the invention pertains, at least in part, to the HCl salt of Compound 1. In another embodiment, the invention pertains, at least in part, to the tosylate (p-toluenesulfonic acid) salt of Compound 1. In another embodiment, the invention pertains, at least in part, to the mesylate salt of Compound 1.

[0012] In another aspect, the invention pertains, at least in part, to a stable crystalline form of Compound 1.

[0013] In another aspect, the invention pertains, at least in part, to a stable crystalline form of a salt of Compound 1. For example, the stable crystalline form of the salt is a stable crystalline form of the tosylate, hydrochloride, or mesylate salt of Compound 1.

[0014] In another embodiment, the invention pertains, at least in part, to polymorphs of Compound 1.

[0015] In another embodiment, the invention pertains, at least in part, to polymorphs of salts of Compound 1.

[0016] For example, the present invention relates to polymorphs of the tosylate salt of Compound 1. The present invention relates, in part, to the Form 1 polymorph of Compound 1. The present invention relates, in part, to the Form 2 polymorph of Compound 1. The present invention relates, in part, to the Form 3 polymorph of Compound 1.

[0017] For example, the Form 1 polymorph of the tosylate salt of Compound 1 has X-ray powder diffraction peaks at about 8.06, 13.02, and 18.83 degrees 2θ using Cu Kα radiation. In some embodiments, the Form 1 polymorph of the tosylate salt of Compound 1 has X-ray powder diffraction peaks at about 8.06, 11.41, 13.02, 18.83, 20.54, and 24.53 degrees 2θ using Cu Kα radiation. In some embodiments, the Form 1 polymorph of the tosylate salt of Compound 1 has X-ray powder diffraction peaks at about 5.60, 8.06, 8.57, 11.41, 13.02, 15.58, 18.83, 20.54, and 24.53 degrees 2θ using Cu Kα radiation.

[0018] For example, the Form 1 polymorph of the tosylate salt of Compound 1 is stable at a temperature ranging from about 0° C. to about 70° C. In some embodiments, the Form 1 polymorph of the tosylate salt of Compound 1 is stable at a temperature ranging from about 5° C. to about 50° C. In some embodiments, the Form 1 polymorph of the tosylate salt of Compound 1 is stable at a temperature ranging from about 20° C. to about 30° C.

[0019] The Form 1 polymorph of the tosylate salt of Compound 1 can be obtained by crystallizing the tosylate salt of Compound 1 from isopropanol.

[0020] For example, the Form 2 polymorph of the tosylate salt of Compound 1 has peaks in an X-ray powder diffraction pattern at 7.82, 11.88, 16.12, and 21.46 degrees 2θ using Cu Kα radiation.

[0021] For example, the Form 3 polymorph of the tosylate salt of Compound 1 has peaks in an X-ray powder diffraction pattern at 5.11, 8.89, 10.34, 11.76, and 15.60 degrees 2θ using Cu Kα radiation.

[0022] In yet another embodiment, the invention includes a pharmaceutical composition comprising a crystalline form of Compound 1 and a pharma- ceutically acceptable diluent, excipient, or carrier.

[0023] For example, pharmaceutical compound compositions of the present invention include compositions comprising a polymorph of Compound 1 and a pharma- ceutically acceptable diluent, excipient, or carrier.

[0024] In another embodiment, the pharmaceutical composition compound of the invention includes a salt of Compound 1 and a pharma- ceutically acceptable diluent, excipient, or carrier. For example, the salt can be a hydrochloride, tosylate, or mesylate salt.

[0025] In one embodiment, the compound of the pharmaceutical composition of the invention includes a polymorph of a salt of Compound 1 and a pharma- ceutically acceptable diluent, excipient, or carrier. For example, the polymorph can be a polymorph of the tosylate, hydrochloride, or mesylate salt of Compound 1.

[0026] In some embodiments, the pharmaceutical composition comprises a polymorph of Compound 1 or a salt thereof in pure form.

[0027] In another embodiment, the pharmaceutical composition of the invention includes a polymorph of the tosylate salt of Compound 1 and a pharma- ceutically acceptable diluent, excipient, or carrier. For example, the polymorph can be the Form 1, Form 2, or Form 3 polymorph of the tosylate salt of Compound 1.

[0028] In some embodiments, the pharmaceutical compositions comprise a polymorph of the tosylate, hydrochloride, or mesylate salt of Compound 1 in pure form.

[0029] In another aspect of the invention, salts of Compound 1 are more stable than the free base of Compound 1.

[0030] In another aspect, the invention includes a method for preparing a stable crystalline form of Compound 1.

[0031] In another embodiment, the invention includes a method for preparing a stable crystalline form of a salt of Compound 1. For example, the stable crystals can be crystals of the tosylate, hydrochloride, or mesylate salt of Compound 1.

[0032] In another embodiment, the invention includes a method for preparing a polymorph of a salt of Compound 1. For example, the polymorph can be a polymorph of the tosylate, hydrochloride, or mesylate salt of Compound 1.

[0033] In another embodiment, the invention includes a method for preparing a polymorph of a tosylate salt of Compound 1. For example, the polymorph can be the Form 1, Form 2, or Form 3 polymorph of the tosylate salt of Compound 1.

[0034] In one embodiment, the present invention includes a method for preparing Form 1 of the polymorph of the tosylate salt of Compound 1, comprising combining Compound 1 with a solvent to produce a slurry, and adding p-toluenesulfonic acid. For example, the solvent can be an alcohol solvent, such as isopropanol. The p-toluenesulfonic acid is provided in an amount of 25-75% by weight relative to the amount of Compound 1, such as 25-50% by weight, 30-40% by weight, or 33% by weight relative to the amount of Compound 1. For example, the p-toluenesulfonic acid is provided in the form of p-toluenesulfonic acid monohydrate.

[0035] For example, the slurry is warmed prior to the addition of p-toluenesulfonic acid.

[0036] For example, the slurry is stirred prior to adding p-toluenesulfonic acid. For example, the stirring is performed at a temperature in the range of 20-25° C. For example, the stirring is performed for 10-24 hours.

[0037] For example, the slurry is dried, e.g., the water content of the supernatant of the slurry is in the range of 0.2-1.0 mg / mL, or in the range of 0.4-0.8 mg / mL.

[0038] In yet another embodiment, the invention includes a method for preparing the Form 1 polymorph of the tosylate salt of Compound 1, comprising preparing a solution of Compound 1 in a solvent or mixture of solvents and adding a solution of p-toluenesulfonic acid to the solvent or mixture of solvents.

[0039] For example, the solvent is an alcohol solvent, such as methanol, ethanol, or isopropanol. For example, the solvent mixture includes an alcohol solvent. For example, the solvent mixture further includes a second alcohol solvent. For example, the solvent mixture includes ethanol and isopropanol. For example, the solvent mixture includes an anti-solvent, such as a ketone, an ether, and an ester. For example, the ether includes, but is not limited to, methyl-t-butyl ether. For example, the solvent mixture includes an alcohol solvent and an anti-solvent. For example, the solvent mixture includes methanol and methyl-t-butyl ether.

[0040] For example, p-toluenesulfonic acid is provided in an amount of 25-75 wt%, 30-50 wt%, 35-45 wt%, or 40 wt% relative to the amount of Compound 1. For example, p-toluenesulfonic acid is provided in the form of p-toluenesulfonic acid monohydrate.

[0041] For example, the solution is prepared at a temperature in the range of 0-60°C, at a temperature in the range of 15-45°C, or at a temperature in the range of 20-25°C.

[0042] For example, the solution may be warmed after preparation, for example, the solution may be maintained at a temperature in the range of 20-50°C, or at about 45°C.

[0043] For example, the method further includes adding seed crystals of the monotosylate salt of Compound 1 to produce a slurry. The slurry may be stirred for 10 to 24 hours, or about 22 hours. The slurry may be stirred at a temperature ranging from 15 to 45° C., or about 20° C. The slurry may be dried. For example, the water content of the slurry is in the range of 1 to 10% by weight, in the range of 2 to 6% by weight, or about 3% by weight.

[0044] In another embodiment, the invention includes a method of preparing the Form 1 polymorph of the tosylate salt of Compound 1, comprising: dissolving the free base of Compound 1 in a first solvent or solvent mixture to form a first solution; dissolving p-toluenesulfonic acid in a second solvent or solvent mixture to form a second solution; and combining the first and second solutions to form a third solution.

[0045] In one embodiment, the first and second solvents or solvent mixtures can be the same or different. In another embodiment, the solvent can be an alcohol solvent, such as methanol, ethanol, and isopropanol. In another embodiment, the solvent mixture is a mixture of two alcohol solvents, including but not limited to ethanol and isopropanol. In a preferred example, the volume to volume ratio of ethanol and isopropanol is 2:1. In yet another embodiment, the solvent mixture is a mixture including but not limited to a combination of an alcohol solvent and an antisolvent (e.g., ketone, ether, ester, etc.). For example, the solvent mixture is a mixture including but not limited to methanol and methyl-t-butyl ether. In a preferred example, the volume to volume ratio of methanol and methyl-t-butyl ether is 1:1.2.

[0046] In another embodiment, the method further comprises adding the Form 1 polymorph tosylate salt of Compound 1 to the third solution to form a fourth solution. For example, the Form 1 polymorph tosylate salt is a seed crystal. In some embodiments, the fourth solution forms a slurry upon stirring. The slurry may be washed with a solvent or solvent mixture that may be the same or different from the first solvent or solvent mixture or the second solvent or solvent mixture. The slurry may be dried.

[0047] In another aspect, the present invention relates to a pure composition comprising Compound 1, which is about 90-100%, preferably 95-100%, more preferably 98-100% (w / w) or 99-100% (w / w) pure, e.g., having less than about 10%, less than about 5%, less than about 2%, or less than about 1% of impurities present, such as, for example, degradation products, oxidation products, epimers, solvents, and / or other undesirable impurities.

[0048] In yet another embodiment, the invention includes a method for treating a tetracycline responsive state in a subject by administering to the subject an effective amount of a crystalline form of Compound 1. For example, the subject is a human subject.

[0049] In yet another embodiment, the invention includes a method for treating a tetracycline responsive state in a subject by administering to the subject an effective amount of a stable salt of Compound 1. For example, the stable salt is a tosylate, hydrochloride, or mesylate salt of Compound 1.

[0050] In yet another embodiment, the invention includes a method for treating a tetracycline responsive state in a subject by administering to the subject an effective amount of a polymorph of Compound 1.

[0051] In yet another embodiment, the invention includes a method for treating a tetracycline responsive state in a subject by administering to the subject an effective amount of a polymorph of a salt of Compound 1. For example, the polymorph can be a polymorph of the tosylate, hydrochloride, or mesylate salt of Compound 1.

[0052] In yet another embodiment, the invention includes a method for treating a tetracycline responsive state in a subject by administering to the subject an effective amount of a polymorph of the tosylate salt of Compound 1. For example, the tosylate polymorph can be the Form 1, Form 2, or Form 3 polymorph of the tosylate salt of Compound 1.

[0053] For example, the tetracycline responsive state is a bacterial infection. The bacterial infection can be associated with gram-positive bacteria or gram-negative bacteria. In some embodiments, the bacterial infection is associated with E. coli, S. aureus, or E. faecalis.

[0054] In some embodiments, the bacterial infection is resistant to other tetracycline antibiotics, including but not limited to tetracycline, minocycline, doxycycline, sancycline, chlortetracycline, demeclocycline, oxytetracycline, kerocardine, rolitetracycline, lymecycline, methacycline, apicycline, clomocycline, pipacycline, mepircycline, meglucycline, guamecycline, penimocycline, and ethamocycline. [The present invention 1001] The crystalline form of compound 1: TIFF2024169444000002.tif27128. [The present invention 1002] Tosylate salt of compound 1: TIFF2024169444000003.tif27128. [The present invention 1003] A crystalline form of the salt of the present invention 1002. [The present invention 1004] A polymorph of the crystalline form of 1003 of the present invention, characterized by an X-ray powder diffraction pattern substantially similar to the pattern depicted in FIG. [The present invention 1005] A polymorph of 1004 of the present invention characterized by an X-ray powder diffraction pattern containing peaks at about 8.06, 13.02, and 18.83 degrees 2θ using Cu Kα radiation. [The present invention 1006] A polymorph of 1004 of the present invention characterized by an X-ray powder diffraction pattern containing peaks at about 8.06, 11.41, 13.02, 18.83, 20.54, and 24.53 degrees 2θ using Cu Kα radiation. [The present invention 1007] A polymorph of 1004 of the present invention characterized by an X-ray powder diffraction pattern containing peaks at about 5.60, 8.06, 8.57, 11.41, 13.02, 15.58, 18.83, 20.54, and 24.53 degrees 2θ using Cu Kα radiation. [The present invention 1008] A polymorph of 1004 according to the present invention obtained by crystallizing the tosylate salt of compound 1 from isopropanol: TIFF2024169444000004.tif27129. [The present invention 1009] dissolving the free base of Compound 1 in a first solvent or mixture of solvents to form a first solution; dissolving p-toluenesulfonic acid in a second solvent or mixture of solvents to form a second solution; and Combining the first solution with the second solution to form a third solution. A method for preparing a stable crystalline tosylate salt of compound 1 comprising: TIFF2024169444000005.tif27130. [The present invention 1010] The method of any one of claims 1009 to 120, wherein the first solvent or solvent mixture and the second solvent or solvent mixture are the same or different. [The present invention 1011] The method of claim 1009, wherein the first solvent mixture and the second solvent mixture are each independently a mixture of alcohol solvents. [The present invention 1012] The method of claim 1011, wherein each solvent mixture is independently a mixture of two alcohol solvents. [The present invention 1013] The method of claim 1012, wherein the two alcohol solvents are ethanol and isopropanol. [The present invention 1014] The process of claim 1013, wherein the volume to volume ratio of ethanol and isopropanol is 2:1. [The present invention 1015] The method of claim 1009, wherein each solvent mixture comprises an alcohol solvent and an antisolvent. [The present invention 1016] The method of claim 1015, wherein the alcohol solvent is methanol. [The present invention 1017] The method of claim 1015, wherein the antisolvent is selected from ketones, ethers, and esters. [The present invention 1018] The process of claim 1017, wherein the ether is methyl t-butyl ether. [The present invention 1019] The process of claim 1009, wherein each of the solvent mixtures comprises methanol and methyl t-butyl ether. [The present invention 1020] The process of claim 1019, wherein the volume to volume ratio of methanol and methyl-t-butyl ether is 1:1.2. [The present invention 1021] 1009. The process of claim 10, wherein p-toluenesulfonic acid is provided in an amount of 25-75% by weight relative to the amount of compound 1. [The present invention 1022] The process of claim 1009, wherein the p-toluenesulfonic acid is provided in the form of p-toluenesulfonic acid monohydrate. [The present invention 1023] The process of claim 1009, further comprising the step of adding the Form 1 polymorph tosylate salt of Compound 1 to the third solution to form a fourth solution. [The present invention 1024] The method of claim 1023, wherein the fourth solution forms a slurry upon agitation. [The present invention 1025] The method of claim 1024 further comprising drying the slurry. [The present invention 1026] The polymorph of the tosylate salt of compound 1 obtained according to the process of the present invention: TIFF2024169444000006.tif27128. [The present invention 1027] A pharmaceutical composition comprising a crystalline salt of 1003 of the present invention and a pharma- ceutically acceptable diluent, excipient, or carrier. [The present invention 1028] A pharmaceutical composition comprising a polymorph of the present invention 1004 and a pharma- ceutically acceptable diluent, excipient, or carrier. [The present invention 1029] A pharmaceutical composition of 1028 of the present invention, wherein the polymorph is present in pure form. [Brief description of the drawings]

[0055] [Figure 1] 1 provides an X-ray powder diffraction pattern at 25° C. of a sample containing crystalline Compound 1. [Diagram 2] 1 provides X-ray powder diffraction patterns at 25° C. of the starting material (E00285), tosylate salt Form 1, tosylate salt Form 2, tosylate salt Form 3, and amorphous tosylate salt forms of Compound 1. [Diagram 3] 1 provides a comparison of X-ray powder diffraction patterns at 25° C. of crystalline Compound 1 (E00285) and a sample containing Form 1 tosylate salt obtained from recrystallization of the amorphous tosylate salt of Compound 1 in IPA. [Figure 4] 1 provides a comparison of X-ray powder diffraction patterns at 25° C. for samples containing tosylate salt Form 1, tosylate salt Form 2, and tosylate salt Form 3 that were dried under vacuum overnight. [Diagram 5] 1 provides X-ray powder diffraction analyses of samples containing the Form 2 tosylate salt at various temperatures. [Figure 6] 1 provides X-ray powder diffraction analyses of samples containing the Form 3 tosylate salt at various temperatures. [Figure 7] 1 provides X-ray powder diffraction analyses at various temperatures of samples comprising slurries of a 50:50 mixture of tosylate salts of types 1 and 3 in IPA. [Figure 8] 1 provides a high-resolution X-ray powder diffraction pattern of a sample containing the Form 1 tosylate salt of Compound 1. [Figure 9] FIG. 1 provides a high resolution X-ray powder diffraction pattern of a sample containing the Form 2 tosylate salt of Compound 1 (93.2% HPLC purity). [Figure 10] FIG. 1 provides a high resolution X-ray powder diffraction pattern of a sample containing the Form 3 tosylate salt of Compound 1 (96.7% HPLC purity). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0056] Detailed Description of the Invention Tetracycline-type antibiotic compounds have long been known to have limited stability in the solid-phase free base form. One such amorphous form of tetracycline analogue compound, (4S,4AS,5AR,12AS)-4-7-bis(dimethylamino)-9{[(2,2-dimethylpropyl)amino]methyl}-3,10,12,12A-tetrahydroxy-1,11-dioxo-1,4,4A,5,5A,6,11,12A-octahydrotetracene-2-carboxamide (compound 1; MW = 556.66, MF = C 29 H 40 N4O7) has limited stability in the solid phase when exposed to air, light, and / or moisture. TIFF2024169444000007.tif27128(4S,4AS,5AR,12AS)-4-7-Bis(dimethylamino)-9{[(2,2-dimethylpropyl)amino]methyl}-3,10,12,12A-tetrahydroxy-1,11-dioxo-1,4,4A,5,5A,6,11,12A-octahydrotetracene-2-carboxamide

[0057] Specifically, compound 1 is a yellow amorphous solid that is unstable at temperatures above 0° C. and when exposed to air. Compound 1 must be stored in the solid phase with limited exposure to air, light, and moisture and at temperatures below 0° C. Outside of these limited exposure conditions, compound 1 decomposes to produce degradation products that include the air degradation products 2, 3, and 4 as well as the 4-epi isomer 5. TIFF2024169444000008.tif62142

[0058] Prior to the present disclosure, no stable crystalline forms or stable crystalline acid salts of Compound 1 were known.

[0059] The present invention relates to crystalline Compound 1, salt forms of Compound 1, polymorphic forms of Compound 1, or polymorphic forms of a salt of Compound 1; pharmaceutical compositions comprising the crystalline forms, salt forms, polymorphic forms, or polymorphic forms of a salt of Compound 1; methods of making the crystalline forms, salt forms, polymorphic forms, or polymorphic forms of a salt of Compound 1; and methods of using them to treat tetracycline responsive states.

[0060] 1.Solid form compounds Compound 1 is a tetracycline compound. The term "tetracycline compound" includes many compounds that have a ring structure similar to tetracycline. Examples of tetracycline compounds include: tetracycline, chlortetracycline, oxytetracycline, demeclocycline, methacycline, sancycline, doxycycline, and minocycline.

[0061] The free base and certain pharma- ceutically acceptable salts of Compound 1 are described in U.S. Patent Application Serial No. 10 / 786,881, which corresponds to U.S. Patent Application Publication No. 2005 / 0026876 A1. As judged by the list of properties above, there is no teaching or suggestion regarding the crystalline form of Compound 1, or that any of the described salt forms are superior to the others.

[0062] Thus, the present invention addresses the need for improved tetracycline compounds, and the need for improved solid state forms of tetracycline compounds for manufacturing and bioavailability.

[0063] Compound 1, the solid-state form of the tetracycline compound, can be in crystalline form. The crystalline form of the compound can be a free base. Different crystalline forms of salts of the free base compound can be formed. Examples of acids that can be used to convert the free base to a salt include, but are not limited to, hydrochloric acid, p-toluenesulfonic acid, trifluoroacetic acid, methylsulfonic acid, benzenesulfonic acid, and acetic acid.

[0064] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0065] As described herein, a process has been developed that can produce different crystalline forms of compound 1. More specifically, the inventors have shown that the crystalline form obtained depends mainly on the nature of the solvent used in the process. For the purposes of this description, the term "crystalline form" refers indistinguishably to either polymorphic or amorphous forms. "Polymorphic form" refers to an organized structure that contains only molecules of solute and has a characteristic crystalline signature.

[0066] The terms "polymorph" and "polymorphic form" and related terms herein refer to crystalline forms of the same molecule, and different polymorphs may have different physical properties, such as melting temperature, heat of fusion, solubility, dissolution rate, and / or vibrational spectrum as a result of molecular alignment or conformation in the crystal lattice. The differences in physical properties exhibited by polymorphs affect pharmaceutical parameters such as storage stability, compressibility and density (important in formulation and product manufacturing), and dissolution rate (an important factor in bioavailability). Differences in stability can also be due to changes in chemical reactivity (e.g., differential oxidation such that a dosage form containing one polymorph loses color more quickly than one containing another polymorph), or mechanical properties (e.g., tablets shatter on storage when a kinetically favorable polymorph transforms into a thermodynamically more stable polymorph), or both (e.g., tablets of one polymorph are more susceptible to degradation at high humidity). As a result of differences in solubility / dissolution, at one extreme, the same polymorphic transition may result in lack of efficacy or, at the other extreme, toxicity. In addition, the physical properties of the crystal may be important during processing, e.g., one polymorph may have a higher tendency to form solvates or may be difficult to filter and wash to remove impurities (i.e., particle shape and size distribution may differ for different polymorphs).

[0067] Polymorphs of a molecule can be obtained by a number of methods, as known in the art, including, but not limited to, melt recrystallization, melt cooling, solvent recrystallization, desolvation, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, and sublimation.

[0068] Techniques for characterizing polymorphs include, but are not limited to, differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), single crystal X-ray diffractometry, vibrational spectroscopy such as IR and Raman spectroscopy, solid state NMR, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography, as well as quantitative analysis, particle size analysis (PSA), surface area analysis, solubility testing, and dissolution testing.

[0069] As used herein, the term "solvate" refers to a crystalline form of a substance that contains a solvent. The term "hydrate" refers to a solvate where the solvent is water.

[0070] A desolvated solvate is a crystalline form of a substance that can only be produced by removing the solvent from the solvate.

[0071] As used herein, the term "amorphous form" refers to a non-crystalline form of a substance.

[0072] The term "pure" as used herein means a compound that is about 90-100%, preferably 95-100%, more preferably 98-100% (wt / wt) or 99-100% (wt / wt) pure; e.g., less than about 10%, less than about 5%, less than about 2%, or less than about 1% of impurities are present. Such impurities include, for example, degradation products, oxidation products, epimers, solvents, and / or other undesirable impurities.

[0073] As used herein, a compound is "stable" if no significant amount of decomposition products are observed over a period of 4 weeks under certain conditions of humidity, light exposure, and temperatures above 0°C. A compound is considered not stable under certain conditions if decomposition impurities appear or the area percentage of existing impurities begins to grow. The amount of decomposition product growth as a function of time is important to determine the stability of a compound.

[0074] All ranges described herein are intended to encompass all included values ​​and ranges, including not only the endpoints of the ranges stated, but also values ​​and ranges not specifically recited.

[0075] The present invention is directed to crystalline forms, salt forms, and polymorphs of Compound 1; compositions comprising the crystalline forms, salts, and polymorphs, alone or in combination with other active ingredients; methods of preparing the crystals, salts, and polymorphs; and methods of using them in modulating tetracycline compound reception. Without intending to be bound by any particular theory of operation, the storage stability, compressibility, density, or dissolution properties of the crystalline forms, salts, and polymorphs are beneficial to the manufacture, formulation, and bioavailability of tetracycline compounds.

[0076] The preferred salts and polymorphs of the present invention are those characterized by physical properties, such as stability, solubility, hygroscopicity, and dissolution rate, suitable for clinical and therapeutic dosage forms. The preferred polymorphs of the present invention are those characterized by physical properties, such as crystalline morphology, compressibility, and hardness, suitable for the manufacture of solid dosage forms. Such properties may be determined using techniques such as X-ray diffraction, microscopy, IR spectroscopy, thermal analysis, and hygroscopicity analysis, as described herein and known in the art.

[0077] 1.1 Salts of Compound 1 In one aspect, the present invention provides crystalline forms of certain pharma- ceutically acceptable salts of Compound 1. This aspect of the invention provides crystalline forms of the hydrochloride, mesylate, and tosylate salts of Compound 1: TIFF2024169444000009.tif27128(4S,4AS,5AR,12AS)-4-7-Bis(dimethylamino)-9{[(2,2-dimethylpropyl)amino]methyl}-3,10,12,12A-tetrahydroxy-1,11-dioxo-1,4,4A,5,5A,6,11,12A-octahydrotetracene-2-carboxamide.

[0078] Each salt of the present invention can be made from the preparation of compound 1. Compound 1 can be synthesized or obtained according to any method that is obvious to those skilled in the art. In a preferred embodiment, compound 1 is prepared according to the method described in detail in the following examples. For example, see US Patent Application Publication No. 2005 / 0026876 A1, the contents of which are incorporated herein by reference in their entirety.

[0079] Alternatively, compound 1 can be prepared by isolating a particular salt of compound 1 and converting such salt to the neutral form of compound 1 by treatment with a suitable base. For example, compound 1 can be prepared by isolating the hydrochloride salt of compound 1 by filtration and then converting it to the neutral form by treatment with monobasic sodium carbonate or other suitable base in ethyl acetate.

[0080] Compound 1, prepared by any method, can be contacted with an appropriate acid, either neat (i.e., not mixed or diluted), or in a suitable inert solvent or solvents, to produce a salt form of the invention. For example, compound 1 can be contacted with p-toluenesulfonic acid to produce a tosylate salt form of the invention.

[0081] Stability studies were performed on the free base of Compound 1 and the amorphous dihydrochloride salt of Compound 1. The salt was formed by dissolving the compound in aqueous solution and adjusting the pH of the solution to about 4.2 followed by lyophilization. The free base decomposed in less than one month at 40° C. and about three months at 4° C. In contrast, the dihydrochloride salt of Compound 1 was stable for six months at 40° C. and for two years at room temperature (25° C.).

[0082] As shown in detail in the examples below, the tosylate salt of Compound 1 and its polymorphs exhibit desirable properties.

[0083] 1.2 Polymorphs of Compound 1 The present invention also provides polymorphs of Compound 1. In certain embodiments, the polymorphs of the present invention are polymorphs of the tosylate salt of Compound 1.

[0084] Each polymorph of the present invention can be made from a preparation of Compound 1. The polymorphic forms of the present invention can be produced by dissolving solid Compound 1 and then crystallizing from the solvent mixtures described below. In certain embodiments of the present invention, the tosylate salt of Compound 1 can be dissolved and then crystallized from the solvent mixtures described below to produce certain polymorphic forms of the present invention. In some embodiments of the present invention, the free base of Compound 1 is dissolved and then an acid is added to form a crystalline salt of Compound 1.

[0085] In one embodiment, the present invention provides a polymorph of the tosylate salt of Compound 1.

[0086] In a further embodiment, the present invention provides a Form 1 polymorph of the tosylate salt of Compound 1 having an X-ray powder diffraction pattern similar to that of Figure 8, all of the features of which are set forth in Table 1. For example, a particular Form 1 polymorph of the present invention has X-ray powder diffraction pattern peaks at 5.60, 8.06, 8.57, 11.41, 13.02, 15.58, 18.83, 20.54, and 24.53 °2θ using Cu Kα radiation. For example, a particular Form 1 polymorph of the present invention has X-ray powder diffraction pattern peaks at 8.06, 11.41, 13.02, 18.83, 20.54, and 24.53 °2θ using Cu Kα radiation. For example, a particular Form 1 polymorph of the present invention has X-ray powder diffraction pattern peaks at 8.06, 13.02, 18.83, and 24.53 °2θ. For example, the particular Form 1 polymorph of the present invention has major X-ray powder diffraction pattern peaks at 8.06 and 18.83 degrees 2θ.

[0087] [Table 1]

[0088] In another embodiment, the present invention provides a Form 2 tosylate salt of Compound 1. In one embodiment, the Form 2 polymorph of the tosylate salt of Compound 1 has an X-ray powder diffraction pattern similar to that of FIG. 9, and the characteristics of this diffraction pattern are all set forth in Table 2. For example, a particular Form 2 polymorph of the present invention has X-ray powder diffraction pattern peaks at 7.82, 11.88, 12.68, 16.12, 18.63, 21.46, and 23.74 degrees 2θ using Cu Kα radiation. For example, a particular Form 2 polymorph of the present invention has major X-ray powder diffraction pattern peaks at 7.82, 11.88, 16.12, and 21.46 degrees 2θ. For example, a particular Form 2 polymorph of the present invention has X-ray powder diffraction pattern peaks at 11.88, and 16.12 degrees 2θ.

[0089] [Table 2]

[0090] In yet another embodiment, the present invention provides Form 3 of Compound 1. In a further embodiment, the Form 3 polymorph of the tosylate salt of Compound 1 has an X-ray powder diffraction pattern similar to that of FIG. 10, and the characteristics of this diffraction pattern are all set forth in Table 3. For example, the particular Form 3 polymorph of the present invention has X-ray powder diffraction pattern peaks at 5.11, 8.89, 10.34, 11.76, 13.70, 14.81, and 15.60° 2θ using Cu Kα radiation. For example, the particular Form 3 polymorph of the present invention has major X-ray powder diffraction pattern peaks at 5.11, 8.89, 10.34, 11.76, and 15.60° 2θ. For example, the particular Form 3 polymorph of the present invention has major X-ray powder diffraction pattern peaks at 5.11 and 15.60° 2θ.

[0091] [Table 3]

[0092] The tosylate salt of Compound 1 crystallized as very small irregular particles, typically 5-8 microns in size. Figure 1 shows the X-ray powder diffraction (XRPD) of a crystalline solid of the tosylate salt of Compound 1. The compound was shown to decompose after melting at 190°C.

[0093] Gravimetric vapor sorption was performed on compound 1 or its tosylate salt. It was determined that there were 2.5 molecules of water per molecule of compound 1. XRPD was performed to compare the starting material (E00285) to the dehydrated material. The data showed no change in morphology.

[0094] 2. Synthesis of Compound 1 9-(aminomethyl)-minocycline dihydrochloride (200 mg, 1 eq.), DMF, and trimethylacetaldehyde (45 μL, 1 eq.) were combined and stirred in a 40 mL flask. Triethylamine (150 μL, 3 eq.) was then added. After stirring for a few minutes at room temperature, NaBH(OAc)3 (175 mg, 2 eq.) and InCl3 (9 mg, 0.1 eq.) were added. After 1 hour, the reaction was clear and red. Liquid chromatography showed one product of the reaction. The reaction was quenched with methanol, the solvent was removed, and the product was purified using column chromatography.

[0095] purification Compound 1 was purified by chromatography by injecting a low pH aqueous solution of the compound into an HPLC with a polar organic solvent gradient and combining the product fractions as the compound was purified. Selection of a suitable acidic mobile phase enhanced the stability and selectivity of the process. Organic and inorganic acidic mobile phases were effective in separating epimeric impurity-containing and closely eluting by-products through pH control or acid selection. Acidic mobile phases also prevented oxidative degradation of the compound.

[0096] For example, the low pH solution had a pH of about 2-3. Examples of solutions used include 0.1% methanesulfonic acid in water and 0.1% trifluoroacetic acid in water. In certain embodiments, an isocratic gradient of 94% water and 6% acetonitrile or another polar organic solvent was used to purify the compound from epimeric and closely eluting by-products.

[0097] The resulting aqueous product fractions may be combined and the pH adjusted to about 4.0-4.5 with a base (e.g., NaOH). Hydrophobic impurities and oxidative decomposition products of the compound may be removed by washing the aqueous solution with a non-polar organic solvent (e.g., CH2Cl2). The organic layer was discarded and the aqueous layer was combined and retained.

[0098] It should be noted that organic solvents such as methylene chloride can be used to selectively remove slow eluting hydrophobic impurities such as the 4-carbonyl by-product and other oxidative decomposition products from acidic aqueous solutions of the compounds.

[0099] The pH of the combined aqueous layers may then be adjusted to a neutral pH, for example, about 7.5 to about 8.5. The pH may be adjusted by adding a base, such as NaOH. The neutral solution is then washed with a non-polar organic solvent, such as methylene chloride. It should be noted that selective pH adjustment to the neutral pH range extracts the compound into the organic solvent while retaining the undesired β-epimer and by-products in the aqueous phase.

[0100] In addition, antioxidants may be added to the aqueous solutions of the compounds described herein as well. Antioxidants may be provided to prevent oxidative degradation of the compounds. Antioxidants such as ammonium sulfite or bisulfite may be used.

[0101] 3. Methods for Preparing Polymorphic Forms of Compound 1 The present invention also relates to methods for preparing crystalline Compound 1 polymorphic forms.

[0102] In one embodiment, Form 1 of the tosylate salt of Compound 1 can be made by any method of making Form 1 that would be obvious to one skilled in the art based on the teachings herein. In certain embodiments, Form 1 can be formed from aging the amorphous tosylate salt of Compound 1 in isopropanol, acetone, ethyl acetate, methylpentanone, toluene, or acetonitrile solution. Form 1 can also be obtained from recrystallization of the amorphous tosylate salt slurried in isopropanol. Form 1 can also be obtained by dissolving the free base in a suitable solvent or mixture of solvents, such as two alcohols, or an alcohol and an antisolvent, such as a ketone, ether, ester, etc. After adding an acid, the salt can be gradually crystallized in the correct form.

[0103] A solvent system can be chosen in which the impurities and the free base of Compound 1 are soluble, but a stable crystalline salt of Compound 1 is insoluble, eg, a crystalline slurry can be formed by precipitation.

[0104] In another embodiment, Form 2 of the tosylate salt of Compound 1 can be made by any method apparent to one of skill in the art based on the teachings herein to make Form 2. In a particular embodiment, Form 2 can be formed from aging of the amorphous tosylate salt of Compound 1 in dichloromethane.

[0105] In another embodiment, Form 3 of the tosylate salt of Compound 1 can be made by any method apparent to one of skill in the art based on the teachings herein to make Form 3. In certain embodiments, Form 3 can be formed from aging of the amorphous tosylate salt of Compound 1 in methyl ethyl ketone, ethyl acetate, or methylpentanone. Form 3 can also be obtained from aging of Form 1 in methylpentanone.

[0106] In a further embodiment, the aforementioned polymorphic forms of the tosylate salt of Compound 1 may be produced by a method that includes combining Compound 1 with a solvent to produce a slurry, and adding p-toluenesulfonic acid.

[0107] Any suitable solvent may be used to make the slurry. In embodiments, the solvent may be used to make the solution from which the salt crystallizes, such as alcoholic solvents, such as isopropanol. Any suitable solvent mixture may be used to make the solution from which the salt crystallizes. In embodiments, the solvent mixture may be used to make the solution from which the salt crystallizes, such as but not limited to methanol and methyl-t-butyl ether, or ethanol and isopropanol.

[0108] For example, a slurry of Compound 1 in a solvent or solvent mixture may be produced at a temperature of about 0° C. to about 60° C., such as about 15° C. to about 45° C., or about 20° C. to about 25° C. After production, the slurry may optionally be warmed and / or maintained at a temperature of about 15° C. to about 60° C., such as about 20° C. to about 50° C., or about 45° C.

[0109] After making the slurry, p-toluenesulfonic acid may be added in an amount sufficient to produce the p-toluenesulfonate salt of Compound 1. In one embodiment, the p-toluenesulfonic acid is provided in an amount of about 25 to about 75 wt%, about 25 to about 50 wt%, about 30 to about 40 wt%, or about 33 wt% based on the amount of Compound 1. The p-toluenesulfonic acid may be added in the form of p-toluenesulfonic acid monohydrate.

[0110] Polymorphic forms of the tosylate salt of Compound 1 can be formed by solution processes. For example, a solution of Compound 1 can be produced at a temperature of about 0° C. to about 60° C., such as about 15° C. to about 45° C., or about 20° C. to about 25° C. After production, the solution can optionally be warmed and / or maintained at a temperature of about 15° C. to about 60° C., such as about 20° C. to about 50° C. or about 45° C.

[0111] After making the solution, p-toluenesulfonic acid may be added in an amount sufficient to produce a p-toluenesulfonate salt of Compound 1. In one embodiment, the p-toluenesulfonic acid is provided in an amount of about 25 to about 75 wt%, about 30 to about 50 wt%, about 35 to about 45 wt%, or about 40 wt% based on the amount of Compound 1. The p-toluenesulfonic acid may be added in the form of p-toluenesulfonic acid monohydrate.

[0112] In one embodiment, the Form 1 polymorph may be added to seed the solution. Any suitable solvent may be used to form the p-toluenesulfonic acid solution. Suitable solvents include alcoholic solvents such as isopropanol, or solvent mixtures such as methanol and methyl-t-butyl ether. In a preferred embodiment, the volume / volume ratio of methanol to methyl-t-butyl ether is 1:1.2. Suitable solvents include mixtures of two or more alcoholic solvents, such as a mixture of ethanol and isopropanol. In a preferred embodiment, the volume / volume ratio of ethanol to isopropanol is 2:1. In certain embodiments, the p-toluenesulfonic acid solution includes the same solvent used to make the slurry or solution of Compound 1.

[0113] After adding p-toluenesulfonic acid to a suitable solvent, a slurry of the Form 1 polymorph of the tosylate salt of the compound is formed. After adding p-toluenesulfonic acid, the water content of the slurry supernatant may be adjusted to a suitable level. Typically, the water content of the slurry supernatant may range from about 0.2 to about 1.0 mg / mL, such as about 0.4 to about 0.8 mg / mL, for example, about 0.6 mg / mL, about 0.54 mg / mL, etc.

[0114] After addition of p-toluenesulfonic acid, the slurry or solution may be stirred to produce a crystal slurry. Stirring may be for more than 48 hours. However, stirring is typically performed for a period of about 5 to about 36 hours, such as about 10 to about 24 hours or about 18 hours.

[0115] The stirring may be carried out at any temperature suitable for producing a crystal slurry. For example, the slurry may be stirred at a temperature of about 0° C. to about 60° C., such as about 15° C. to about 45° C., or about 20° C. to about 25° C.

[0116] After the crystals are formed, the crystal slurry may be filtered to remove the supernatant, and the crystals may be washed with any suitable solvent. In an embodiment, the crystals may be washed 1-4 times, and the solvent may be any solvent suitable for preparing the crystal slurry. In particular, the solvent used to wash the crystals may be the same solvent or solvents used to form the initial slurry or solution, or the p-toluenesulfonic acid solution.

[0117] The produced crystals may then be dried to remove excess solvent by any suitable method. For example, drying may be accomplished by one or more methods including, but not limited to, elevated temperatures ranging from about 0° C. to about 60° C., such as from about 15° C. to about 45° C.; blowing dry nitrogen over the crystals; and blowing wet nitrogen over the crystals.

[0118] A ripening study was performed in which samples of the tosylate salt of Compound 1 were slurried in different solvents, filtered, and the wet solid was analyzed by XRPD. Three polymorphic forms of the tosylate salt of Compound 1 were observed. Figure 2 shows the XRPD spectra of the starting material (E00285), tosylate salt form 1, tosylate salt form 2, tosylate salt form 3, and the amorphous form of Compound 1.

[0119] Table 4 lists the solvents used in the aging experiments.

[0120] [Table 4]

[0121] Recrystallization of the amorphous material of Compound 1 was performed in various solvents. Only recrystallization in 2-propanol (isopropyl alcohol, IPA) yielded the Form 1 tosylate salt, as shown in Table 5. Figure 3 compares the XRPD spectra of reference Compound 1 (E00285) and the Form 1 tosylate salt recrystallized from IPA.

[0122] [Table 5]

[0123] The polymorphic tosylate salt of Compound 1 is outlined in Scheme 1. TIFF2024169444000015.tif68129

[0124] After recrystallization, samples of Form 1, Form 2, and Form 3 tosylate salts were dried under vacuum overnight and analyzed by XRPD as shown in Figure 4. There was no change in morphology after drying.

[0125] Variable temperature XRPD was performed on Form 2 and Form 3 tosylate salts of Compound 1. See Figures 5 and 6, respectively.

[0126] The relative stability of the polymorphic forms of compound 1 was analyzed. For example, the form 1 tosylate salt was subjected to a 24 hour aging experiment in either IPA or methylpentanone seeded with either the form 2 or the form 3 tosylate salt. There was no conversion of form 1 to form 2 or 3 during this experiment. A slurry of a 50:50 mixture of forms 1 and 3 was analyzed in IPA at 0° C., 25° C., 40° C., and 60° C. for 18 hours, as shown in FIG. 7. There was no conversion from form 1 to form 3.

[0127] Recrystallization experiments showed that form 1 tosylate salt could be reproducibly obtained from the amorphous tosylate salt by slurry formation in IPA. Form 1 of compound 1 could also be reproducibly obtained by addition of tosylic acid. A high-resolution XRPD scan of form 1 is shown in FIG. 8 and the diffraction pattern characteristics are given in Table 1.

[0128] 4. Pharmaceutical compositions comprising compounds, salts, crystalline forms, or polymorphs of the present invention In a further aspect, the invention relates to a pharmaceutical composition comprising a tetracycline compound of the invention (e.g., synthesized or purified by the methods of the invention) or a pharma- ceutically acceptable salt, prodrug, or ester thereof. The pharmaceutical composition may include a pharma- ceutically acceptable carrier.

[0129] The term "composition" as used herein is intended to encompass not only a product containing the specified ingredients (and, if indicated, the specified amounts), but any product resulting directly or indirectly from the admixture of the specified ingredients in the specified amounts. "Pharmaceutically acceptable" means that the diluent, excipient, or carrier must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0130] As mentioned above, certain embodiments of the compounds of the present invention may contain a basic functional group, such as amino or alkylamino, and thus may form pharma-ceutically acceptable salts with pharma-ceutically acceptable acids. The term "pharma-ceutically acceptable salts" is art-recognized and includes the relatively non-toxic inorganic and organic acid addition salts of the compounds of the present invention. These salts may be prepared in situ during the final isolation and purification of the compounds of the present invention, or by separately reacting the purified compounds of the present invention in their free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, lauryl sulfonate, and the like (see, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Farm. SCI. 66:1-19).

[0131] In other cases, the compounds of the present invention may contain one or more acidic functional groups and thus can form pharma-ceutically acceptable salts with pharma-ceutically acceptable bases. The term "pharma-ceutically acceptable salts" in these instances includes the relatively non-toxic, inorganic and organic base addition salts of the compounds of the present invention. These salts can also be prepared during the final isolation and purification of the compounds, or in situ by reacting the purified compounds in their free acid form separately with a suitable base, such as a hydroxide, carbonate, or bicarbonate of a pharma-ceutically acceptable metal cation, with ammonia, or with a pharma-ceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like.

[0132] The term "pharmaceutical acceptable ester" refers to the relatively non-toxic esterification products of the compounds of the present invention. These esters can be prepared during the final isolation and purification of the compounds or in situ by reacting the purified compounds in their free acid form or hydroxyls separately with a suitable esterifying agent. Carboxylic acids can be converted to esters by treatment with an alcohol in the presence of a catalyst. Hydroxyls can be converted to esters by treatment with an esterifying agent such as an alkanoyl halide. The term also includes lower hydrocarbon groups that can be solvated under physiological conditions, such as alkyl esters, methyl, ethyl, and propyl esters (see, for example, Berge et al., supra).

[0133] The present invention also relates to the tetracycline compounds synthesized and / or purified by the methods of the invention, and pharma- ceutically acceptable salts thereof.

[0134] The phrase "pharmacologically acceptable carrier" is art-recognized and includes pharma-ceutically acceptable materials, compositions, or vehicles suitable for administering a compound of the invention to a mammal. Carriers include liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials involved in carrying or transporting the subject substance from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials which can serve as pharma- ceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffers; and other non-toxic compatible substances used in pharmaceutical preparations.

[0135] Wetting agents, emulsifying agents, and lubricating agents, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening agents, flavoring and perfuming agents, preservatives, and antioxidants can also be present in the composition.

[0136] Examples of pharma- ceutically acceptable antioxidants include: water-soluble antioxidants such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; fat-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, and the like; and metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0137] The formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal, and / or parenteral administration. The formulations may be conveniently presented in unit dosage form and may be prepared by any method well known in the pharmaceutical arts. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of compound that produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, and most preferably from about 10 percent to about 30 percent.

[0138] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier, and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

[0139] Formulations of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (with a flavored base, usually sucrose and acacia or tragacanth), powders, granules, each containing a predetermined amount of a compound of the present invention as the active ingredient, or may be a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion, or an elixir or syrup, or pastille (with an inert base such as gelatin and glycerin, or sucrose and acacia), and / or mouthwash, etc. The compounds of the present invention may also be administered as a bolus, electuary, or paste.

[0140] In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the active ingredient is mixed with one or more pharma- ceutically acceptable carriers such as sodium citrate, or dicalcium phosphate and / or any of the following: fillers or extenders such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; humectants such as glycerol; disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; dissolution retarding agents such as paraffin; absorption accelerators such as quaternary ammonium compounds; humectants such as cetyl alcohol and glycerol monostearate; absorbents such as kaolin and bentonite earth; lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and colorants. In the case of capsules, tablets, and pills, the pharmaceutical compositions may also contain buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0141] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycol or cross-linked sodium carboxymethylcellulose), surface active or dispersing agents. Molded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine.

[0142] Tablets, and other solid dosage forms of pharmaceutical compositions of the present invention, such as dragees, capsules, pills, and granules, may be optionally scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical arts. They may be formulated to provide slow or controlled release of the active ingredient therein, for example, with various ratios of hydroxypropylmethylcellulose, other polymer matrices, liposomes, and / or microspheres to provide a desired release profile. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved in sterile water or any other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents, and may be of a composition that releases the active ingredient only or preferentially in a certain part of the digestive tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient may be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0143] The liquid dosage form for oral administration of the compound of the present invention includes pharmaceutically acceptable emulsion, microemulsion, solution, suspension, syrup and elixir.Besides active ingredient, liquid dosage form may contain water or other inert diluents commonly used in the art, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol and fatty acid ester of sorbitan, and mixtures thereof.

[0144] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0145] In addition to the active compound, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

[0146] Formulations of pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as suppositories, which may be prepared by mixing one or more compounds of the invention with one or more suitable non-irritating excipients or carriers including, for example, cocoa butter, polyethylene glycol, a suppository wax, or a salicylate, which are solid at room temperature but liquid at body temperature and therefore will melt in the rectal or vaginal cavity to release the active compound.

[0147] Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing such carriers as are known in the art to be appropriate.

[0148] Dosage forms for topical or transdermal administration of a compound of the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharma- ceutically acceptable carrier, and any preservatives, buffers, or propellants which may be required.

[0149] The ointments, pastes, creams, and gels may contain, in addition to the active compounds of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof.

[0150] Powders and sprays can contain, in addition to the compounds of the invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0151] Transdermal patches have the added advantage of providing controlled delivery of the compounds of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. Such flux rate can be controlled by either providing a rate-controlling membrane or dispersing the active compound in a polymer matrix or gel.

[0152] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the present invention.

[0153] Pharmaceutical compositions of the present invention suitable for parenteral administration contain one or more compounds of the present invention in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, or sterile powders that may be reconstituted immediately before use in sterile injectable solutions or dispersions which may contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, suspending agents, or thickening agents.

[0154] Examples of suitable aqueous and non-aqueous carriers that may be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.

[0155] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Similarly, it may be desirable to include in the composition isotonic substances, such as sugars, sodium chloride, and the like. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of substances that delay absorption, such as aluminum monostearate and gelatin.

[0156] In some cases, it is desirable to delay the absorption of drugs from subcutaneous or intramuscular injections in order to prolong the effect of the drug. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug depends on its dissolution rate, which in turn can depend on the size and crystalline form of the crystal. Alternatively, delayed absorption of parenterally administered drug forms can be accomplished by dissolving or suspending the drug in an oil vehicle.

[0157] Injectable depot dosage forms are made by forming a microencapsulation matrix of the compound of the present invention in biodegradable polymers such as polylactide-polyglycolide esters.Depending on the drug-to-polymer ratio and the nature of the specific polymer used, the drug release rate can be controlled.Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydride esters).Depot injectable formulations are also prepared by entrapping drug in liposomes or microemulsions that are compatible with body tissues.

[0158] The preparations of the present invention may be administered orally, parenterally, topically, or rectally. They are provided in dosage forms suitable for each administration route. For example, they are administered in the form of tablets or capsules. For example, they are administered by injections, infusions, inhalants, lotions, ointments, suppositories, etc. Oral administration is preferred.

[0159] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.

[0160] As used herein, the phrases "systemic administration," "administered systemically," "peripheral administration," and "administered peripherally" refer to administration of a compound, drug, or other material other than directly into the central nervous system, e.g., subcutaneous administration, such that the compound enters the patient's system and thus is subject to metabolism and other similar processes.

[0161] These compounds may be administered to humans and other animals for treatment by any suitable route of administration, including orally, intranasally (e.g., by spray), rectally, intravaginally, parenterally, intracisternally, and topically (e.g., as powders, ointments, or drops, including buccal and sublingual).

[0162] Regardless of the route of administration selected, the compounds of the present invention, which may be used in suitable hydrated forms and / or pharmaceutical compositions of the present invention, are formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those of skill in the art.

[0163] The term "therapeutically effective amount" refers to that amount of a salt or polymorph of the invention that will elicit the biological or medical response in a tissue, system, animal, or human desired by a researcher, veterinarian, physician, or other clinician, or that is sufficient to prevent the onset of, or alleviate to some extent, one or more of the symptoms of the disease being treated.

[0164] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied to obtain an amount of the active ingredient that is effective to achieve a desired therapeutic response for a particular patient, composition, and mode of administration without causing toxicity to the patient.

[0165] The selected dosage level will depend upon a variety of factors, including the activity of the particular compound of the invention, or esters, salts, or amides thereof, being used, the route of administration, the time of administration, the rate of excretion of the particular compound being used, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular compound being used, the age, sex, weight, condition, overall health and prior medical history of the patient being treated, and similar factors well known in the medical arts.

[0166] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start the dosage of the compound of the present invention used in the pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0167] In general, a suitable daily dose of a compound of the present invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective amount will generally depend on the factors discussed above. In general, when used in relation to the indicated analgesic effect, the intravenous and subcutaneous dose of the compound of the present invention per patient will be in the range of about 0.0001 to about 100 mg / kg body weight / day, more preferably about 0.01 to about 50 mg / kg / day, and even more preferably about 0.1 to about 10 mg / kg / day. For example, in some embodiments, the dose is 0.5 to about 4.0 mg / kg / day. If desired, the effective daily dose of the active compound may be administered as 1, 2, 3, 4, 5, 6 or more subdoses administered individually at appropriate intervals throughout the day, week, or other suitable period, optionally in unit dosage form.

[0168] While it is possible for the compounds of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.

[0169] 5. Methods of Using the Tetracycline Compounds of the Invention The present invention also relates to a method for treating a tetracycline responsive state in a subject by administering to the subject an effective amount of a composition comprising compound 1 according to the present invention or a pharma- ceutically acceptable salt thereof such that the condition is treated.

[0170] As used herein, the terms "treat," "treating," or "treatment" refer to a method of alleviating or eliminating a disease or disorder (e.g., a tetracycline compound responsive state) and / or its associated symptoms. As used herein, the terms "prevent," "preventing," or "prevention" refer to a method of preventing a subject from acquiring a disease or disorder. As used herein, a "subject" includes a mammal. The mammal can be, for example, any mammal, such as a human, a primate, a mouse, a rat, a dog, a cat, a cow, a horse, a goat, a camel, a sheep, or a pig. Preferably, the mammal is a human.

[0171] The term "tetracycline compound responsive state" or "tetracycline responsive state" includes conditions that can be treated, prevented, or otherwise ameliorated by administration of the tetracycline compounds of the present invention. Tetracycline compound responsive states include bacterial, viral, and fungal infections (including infections that are resistant to other tetracycline compounds), cancer (e.g., prostate cancer, breast cancer, colon cancer, lung cancer, melanoma, lymphatic cancer, and other disorders characterized by unwanted cell proliferation, including but not limited to those described in US 6,100,248), arthritis, osteoporosis, diabetes, and other conditions in which tetracycline compounds have been found to be active (see, for example, U.S. Patent Nos. 5,789,395; 5,834,450; 6,277,061, and 5,532,227, each of which is expressly incorporated herein by reference). The compounds of the present invention can be used to prevent or control important mammalian and animal diseases such as diarrhea, urinary tract infections, skin and skin structure infections, ear, nose, and throat infections, wound infections, mastitis, etc. In addition, methods for treating neoplasms with the tetracycline compounds of the present invention are also included (van der Bozert et al., Cancer Res., 1998, 48:6686-6690). In one embodiment, the tetracycline responsive state is not a bacterial infection. In another embodiment, the tetracycline compounds of the present invention are non-antibacterial in nature. For example, the non-antibacterial tetracycline compounds of the present invention may have an MIC of greater than about 4 μg / ml as measured by assays known in the art.

[0172] Tetracycline compound responsive states also include inflammatory process associated states (IPAS). The term "inflammatory process associated states" includes conditions in which inflammation or inflammatory factors (e.g., matrix metalloproteinases (MMPs), nitric oxide (NO), TNF, interleukins, plasma proteins, cellular defense systems, cytokines, lipid metabolism, proteases, toxic radicals, adhesion molecules, etc.) are involved or present in abnormal amounts in an area. The inflammatory process is the response of living tissues to injury. The cause of inflammation may be due to physical injury, chemicals, microorganisms, tissue necrosis, cancer, or other substances. Acute inflammation is short-lived, lasting only a few days. However, if it persists for longer, it may be called chronic inflammation.

[0173] IPAS includes inflammatory disorders. Inflammatory disorders are generally characterized by fever, redness, swelling, pain, or loss of function. Examples of causes of inflammatory disorders include, but are not limited to, microbial infections (e.g., bacterial and fungal infections), physical agents (e.g., burns, radiation, and trauma), chemical agents (e.g., toxins and caustic substances), tissue necrosis, and various types of immune responses. In further embodiments, IPAS includes disorders described in U.S. Patent Nos. 5,929,055 and 5,532,227, the entire contents of which are incorporated herein by reference.

[0174] Examples of inflammatory disorders include, but are not limited to, osteoarthritis, rheumatoid arthritis, acute and chronic infections (bacterial and fungal, including diphtheria and whooping cough), acute and chronic bronchitis, sinusitis, upper respiratory tract infections (such as the common cold), acute and chronic gastroenteritis and colitis, acute and chronic cystitis and urethritis, acute and chronic dermatitis, acute and chronic conjunctivitis, acute and chronic serositis (pericarditis, peritonitis, synovitis, pleuritis and tendonitis), uremic pericarditis, acute and chronic cholecystitis, acute and chronic vaginitis, acute and chronic uveitis, drug reactions, insect bites, burns (thermal, chemical, and electrical), and sunburn.

[0175] The term "inflammatory process-related condition" includes, in one embodiment, NO-related condition. The term "NO-related condition" includes conditions involving or related to nitric oxide (NO) or inducible nitric oxide synthase (iNOS). NO-related condition includes conditions characterized by abnormal amounts of NO and / or iNOS. Preferably, NO-related condition can be treated by administering the tetracycline compound of the present invention. Disorders, diseases, and conditions described in U.S. Patent Nos. 6,231,894; 6,015,804; 5,919,774; and 5,789,395 are also included as NO-related condition. The entire contents of each of these patents are incorporated herein by reference.

[0176] Other examples of NO-associated conditions include malaria, aging, diabetes, vascular stroke, neurodegenerative disorders (Alzheimer's, Huntington's, and Parkinson's diseases), heart disease (reperfusion-related injury after infarction), juvenile diabetes, inflammatory disorders, osteoarthritis, rheumatoid arthritis, acute, recurrent, and chronic infections (bacterial, viral, and fungal), acute and chronic bronchitis, sinusitis, and respiratory infections (such as the common cold), acute and chronic gastrointestinal disorders, and chronic inflammatory bowel disease. These conditions include, but are not limited to, inflammation and colitis, acute and chronic cystitis and urethritis, acute and chronic dermatitis, acute and chronic conjunctivitis, acute and chronic serositis (pericarditis, peritonitis, synovitis, pleuritis, and tendonitis), uremic pericarditis, acute and chronic cholecystitis, cystic fibrosis, acute and chronic vaginitis, acute and chronic uveitis, drug reactions, insect bites, burns (thermal, chemical, and electrical), and sunburn.

[0177] The term "inflammatory process-associated conditions" includes, in one embodiment, matrix metalloproteinase-associated conditions (MMPAS). MMPAS includes conditions characterized by abnormal amounts of MMPs or MMP activity. These are also included as tetracycline compound responsive conditions that may be treated with the compounds of the present invention.

[0178] Examples of matrix metalloproteinase-associated conditions (MMPAS) include atherosclerosis, corneal ulcers, emphysema, osteoarthritis, multiple sclerosis (Liedtke et al., Ann. Neurol. 1998, 44:35-46; Chandler et al., J. Neuroimmunol. 1997, 72:155-71), osteosarcoma, osteomyelitis, bronchiectasis, chronic pulmonary obstructive disease, skin and eye diseases, periodontitis, osteoporosis, rheumatoid arthritis, ulcerative colitis, inflammatory disorders, tumor growth and invasion (Stetler- Stevenson et al., Annu. Rev. Cell Biol. 1993, 9:541-73; Tryggvason et al., Biochim. Biophys. Acta 1987, 907:191-217; Li et al., Mol. Carcinog. 1998, 22:84-89), metastasis, acute lung injury, stroke, ischemia, diabetes, aortic or vascular aneurysm, skin tissue wounds, dry eye, bone and cartilage degradation (Greenwald et al., Bone 1998, 22:33-38; Ryan et al., Curr. Op. Rheumatol 1996, 8:238-247). Other MMPAS include those described in U.S. Patent Nos. 5,459,135; 5,321,017; 5,308,839; 5,258,371; 4,935,412; 4,704,383; 4,666,897; and RE 34,656, the entire contents of which are incorporated herein by reference.

[0179] In another embodiment, the tetracycline compound responsive state is cancer. Examples of cancers that the tetracycline compounds of the present invention may be useful for treating include all solid tumors, i.e., carcinomas, such as adenocarcinomas and sarcomas. Adenocarcinomas are carcinomas that originate from gland-like tissue or whose tumor cells form recognizable glandular structures. Sarcomas broadly include tumors whose cells are embedded in fibrillar or homogeneous substances such as embryonic connective tissue. Examples of carcinomas that may be treated with the compounds of the present invention include, but are not limited to, prostate cancer, breast cancer, ovarian cancer, testicular cancer, lung cancer, colon cancer, and breast cancer. The method of the present invention is not limited to the treatment of these tumor types, but extends to any solid tumor originating from any organ system. Examples of treatable cancers include, but are not limited to, colon cancer, bladder cancer, breast cancer, melanoma, ovarian cancer, prostate cancer, lung cancer, and a variety of other cancers as well. The method of the present invention also causes inhibition of cancer growth in adenocarcinomas, such as prostate cancer, breast cancer, kidney cancer, ovarian cancer, testicular cancer, and colon cancer.

[0180] In one embodiment, the present invention relates to a method for treating a subject suffering from or at risk of suffering from cancer by administering an effective amount of a substituted tetracycline compound so that inhibition of cancer cell growth occurs, i.e., cell proliferation, invasion, metastasis, or tumor development is reduced, delayed, or stopped. Inhibition may be due to inhibition of inflammatory processes, downregulation of inflammatory processes, some other mechanism, or a combination of mechanisms. Alternatively, the tetracycline compounds may be useful for preventing cancer recurrence, for example, for treating residual cancer after surgical resection or radiation therapy. The tetracycline compounds useful according to the present invention are particularly advantageous because they are substantially non-toxic compared to other cancer treatments. In a further embodiment, the compounds of the present invention are administered in combination with standard cancer treatments, such as, but not limited to, chemotherapy.

[0181] Examples of tetracycline-responsive states also include both neuropsychiatric and neurodegenerative disorders, including Alzheimer's disease, dementias related to Alzheimer's disease such as Pick's disease, Parkinson's disease and other diffuse Lewy body diseases, senile dementia, Huntington's disease, Gilles de la Tourette's syndrome, multiple sclerosis, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, epilepsy, and autonomic dysfunction such as Creutzfeldt-Jakob disease, hypertension, and sleep disorders. Neurological disorders include, but are not limited to, neuropsychiatric disorders (such as depression, schizophrenia, schizoaffective disorder, Korsakoff's psychosis, mania, anxiety disorders, phobia disorders, etc.), learning or memory disorders (such as amnesia or age-related memory loss, attention deficit disorder, etc.), dysthymic disorder, major depressive disorder, obsessive-compulsive disorder, psychoactive substance use disorders, anxiety, phobias, panic disorders, as well as bipolar affective disorders (such as severe bipolar affective (mood) disorder (BP-1), bipolar affective neurological disorders, e.g., migraine and obesity). Further neurological disorders include, for example, those disorders described in the American Psychiatric Association's Diagnostic and Statistical manual of Mental Disorders (DSM), the entire contents of the most recent edition of which are incorporated herein by reference.

[0182] In another embodiment, the tetracycline compound responsive state is diabetes, such as juvenile diabetes, diabetes mellitus, type I diabetes, or type II diabetes. In a further embodiment, protein glycosylation is not affected by administration of the tetracycline compound of the invention. In another embodiment, the tetracycline compound of the invention is administered in combination with standard diabetes treatment, such as, but not limited to, insulin treatment.

[0183] In another embodiment, the tetracycline compound responsive state is bone mass disorder.Bone mass disorder includes disorders in which the bone of a subject is disordered and / or conditions in which bone formation, repair or remodeling is beneficial.For example, bone mass disorder includes osteoporosis (e.g., bone strength and density reduction), bone fracture, bone formation associated with surgical techniques (e.g., facial reconstruction), osteogenesis imperfecta (brittle bone disease), hypophosphatasia, Paget's disease, fibrous bone formation disorder, osteopetrosis, myeloma bone disease, and calcium depletion in bone, such as in cases associated with primary hyperparathyroidism.Bone mass disorder includes all conditions in which bone formation, repair or remodeling is beneficial for a subject, as well as all other disorders related to the bone or skeletal system of a subject that can be treated by the tetracycline compound of the present invention. In further embodiments, bone mass disorders include those described in U.S. Pat. Nos. 5,459,135; 5,231,017; 5,998,390; 5,770,588; RE 34,656; 5,308,839; 4,925,833; 3,304,227; and 4,666,897, the entire contents of each of which are incorporated herein by reference.

[0184] In another embodiment, the tetracycline compound responsive state is acute lung injury.Acute lung injury includes adult respiratory distress syndrome (ARDS), post pump syndrome (PPS) and trauma.Trauma includes any injury to living tissue caused by exogenous material or event.Examples of trauma include, but are not limited to, contusion, contact with hard surface, or cut or other injury to lung.

[0185] The present invention also relates to methods for treating acute lung injury by administering a substituted tetracycline compound of the invention.

[0186] The tetracycline-responsive state of the present invention also includes chronic lung disorders.The present invention relates to a method for treating chronic lung disorders by administering tetracycline compounds such as compounds described herein.The present invention includes administering an effective amount of substituted tetracycline compounds to a subject so that chronic lung disorders are treated.Examples of chronic lung disorders include, but are not limited to, asthma, cystic fibrosis, and emphysema.In a further embodiment, the tetracycline compounds of the present invention are used to treat acute and / or chronic lung disorders such as those described in U.S. Patent Nos. 5,977,091; 6,043,231; 5,523,297; and 5,773,430, the entire contents of each of which are incorporated herein by reference.

[0187] In yet another embodiment, the tetracycline compound responsive state is ischemia, stroke, or ischemic stroke.The present invention also relates to a method for treating ischemia, stroke, or ischemic stroke by administering an effective amount of the substituted tetracycline compound of the present invention.In a further embodiment, the tetracycline compound of the present invention is used to treat the disorders described in U.S. Patent Nos. 6,231,894; 5,773,430; 5,919,775; and 5,789,395, which are incorporated herein by reference.

[0188] In another embodiment, the tetracycline compound responsive state is a skin wound. The present invention also relates, at least in part, to a method for improving the healing response of epithelial tissue to acute traumatic injury (e.g., cut, burn, abrasion, etc.). The method may include using a tetracycline compound of the present invention (which may or may not have antibacterial activity) to improve the ability of epithelialized tissue to heal acute wounds. The method may increase the rate of collagen accumulation in the healing tissue. The method may also decrease proteolytic activity in the epithelialized tissue by decreasing collagenolytic and / or gelatinolytic activity of MMPs. In a further embodiment, the tetracycline compound of the present invention is administered to the surface of the skin (e.g., topically). In a further embodiment, the tetracycline compounds of the invention are used to treat skin wounds and other such disorders, e.g., as described in U.S. Pat. Nos. 5,827,840; 4,704,383; 4,935,412; 5,258,371; 5,308,8391; 5,459,135; 5,532,227; and 6,015,804, the entire contents of each of which are incorporated herein by reference.

[0189] In yet another embodiment, the tetracycline compound responsive state is an aortic or vascular aneurysm in vascular tissue of a subject (e.g., a subject having or at risk of having an aortic or vascular aneurysm, etc.). The tetracycline compound may be effective to reduce the size of a vascular aneurysm, or may be administered to a subject prior to the onset of a vascular aneurysm so that the aneurysm is prevented. In one embodiment, the vascular tissue is an artery, such as an aorta, e.g., an abdominal aorta. In a further embodiment, the tetracycline compound of the present invention is used to treat disorders described in U.S. Patent Nos. 6,043,225 and 5,834,449, the entire contents of which are incorporated herein by reference.

[0190] Bacterial infections can be caused by a wide variety of gram-positive and gram-negative bacteria. The compounds of the present invention are useful as antibiotics against organisms that are resistant to other tetracycline compounds. The antibiotic activity of the tetracycline compounds of the present invention is described in Waitz, JA, National Commission for Clinical Laboratory Standards, Document M7-A2, vol. 10, no. 8, pp. 13-20, 2003. nd This may be determined using the standard in vitro broth dilution method described in The Journal of Clinical Chemistry, Vol. 12, No. 1, 1996, 1997.

[0191] The tetracycline compounds may also be used to treat infections that are traditionally treated with tetracycline compounds, such as, for example, rickettsial infections, many gram-positive and gram-negative bacterial infections, lymphogranuloma venereum, inclusion conjunctivitis, and psittacosis. The tetracycline compounds may also be used to treat, for example, K. pneumoniae, Salmonella, E. hirae, A. baumanii, B. catarrhalis, H. influenzae, P. aeruginosa, E. faecium, E. coli, Staphylococcus aureus, or E. faecalis infections. In one embodiment, the tetracycline compounds are used to treat bacterial infections that are resistant to other tetracycline antibiotic compounds. The tetracycline compounds of the invention may be administered with a pharma- ceutically acceptable carrier.

[0192] The term "in combination with" another therapeutic agent or treatment includes simultaneous administration of the tetracycline compound (e.g., an inhibitor) with the other therapeutic agent or treatment, administration of the tetracycline compound followed by administration of the other therapeutic agent or treatment, and administration of the tetracycline compound followed by administration of the other therapeutic agent or treatment. The other therapeutic agent may be any agent known in the art to treat, prevent, or reduce symptoms of a disease or disorder, such as IPAS. Furthermore, the other therapeutic agent may be any agent that is beneficial to a patient when administered in combination with administration of the tetracycline compound. In one embodiment, diseases such as cancer that are treated by the methods of the present invention include diseases described in U.S. Patent Nos. 6,100,248; 5,843,925; 5,837,696; and 5,668,122, the entire contents of which are incorporated herein by reference.

[0193] The term "effective amount" of a compound is an amount that is necessary or sufficient to treat or prevent a tetracycline compound responsive state. The effective amount may vary depending on factors such as the subject's size and weight, the type of illness, or the particular tetracycline compound. For example, the choice of tetracycline compound may affect what constitutes an "effective amount." One of ordinary skill in the art would be able to examine the aforementioned factors and make a determination regarding the effective amount of the tetracycline compound without undue experimentation.

[0194] In the therapeutic methods of the invention, one or more tetracycline compounds of the invention may be administered alone to a subject, or, more typically, the compounds of the invention may be administered as part of a pharmaceutical composition mixed with conventional excipients, i.e., pharma- ceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral, or other desired administration which do not deleteriously react with the active compounds and which are not deleterious to the recipient thereof.

[0195] This invention is further illustrated by the following examples which should not be construed as further limiting. EXAMPLES

[0196] 6. Exemplification of the Invention Example 1: Synthesis of 9-alkylaminomethyl minocycline TIFF2024169444000016.tif128146Minocycline hydrochloride (compound 2) was dissolved in methylsulfonic acid or hydrofluoric acid along with a similar water scavenger acid such as methylsulfonic anhydride or trifluoromethanesulfonic acid. N-hydroxymethylphthalimide was added to the reaction mixture. The mixture was stirred at 20-35°C until the reaction was complete. When the acid solution was added to an ice / water mixture, the triflic acid salt could be easily precipitated for filtration and collection. The solid was redissolved in acetone and brought to neutral pH with base. The product was precipitated by adding water. If triflic acid is present as a scavenger, the product may precipitate without neutralization. The product was isolated as a mixture of bis and tris alkylated products. The isolated material of this reaction was concentrated to the desired bis ratio (90%).

[0197] The solid was suspended in EtOH or MeOH. Aminolysis was carried out with methylamine. As the reaction proceeded, the phthalamide by-product precipitated and was removed by filtration. Addition of approximately 1.5 volumes of t-butyl methyl ether to the reaction mixture precipitated a pale yellow solid product which was collected by simple filtration, leaving many small impurities and the methylamine reagent in solution. Further purification of the compound was achieved through reslurrying with a lower aliphatic alcohol such as methanol.

[0198] Compound 4 as a free base was transferred to a hydrogenation vessel charged with methanol and aldehyde. The vessel was charged with deactivated Pd / C catalyst and pressurized with hydrogen gas. The reaction mixture was hydrogenated under about 30 psi hydrogen pressure for about 24 hours. After the conversion of compound 4 to 1 was complete, the solution was filtered and washed through a Celite pad. At this point, the reaction mixture contained very low βC-4 epimer, about 3-7%.

[0199] Product (1) was worked up as follows to selectively isolate the product from its impurities. The pH of the solution was adjusted to about 4.5 with concentrated HCl and the solution was extracted with dichloromethane. To selectively recover the desired epimeric product (e.g., α), the aqueous layer was extracted with dichloromethane. The dichloromethane layers were combined and concentrated, and 2 L of n-heptane was added to precipitate the product. Further purification was obtained by repeating the preparative technique with or without t-butyl methyl ether to dissolve the crude product.

[0200] Example 2: Purification of Compound 1 Crude 9-(2',2'-dimethylpropylaminomethyl)minocycline free base (40 g) was dissolved in 150 mL of buffer A (0.1% methanesulfonic acid in water - MSA) and the pH was adjusted to 2-3 with MSA.

[0201] The solution was filtered and injected into the HPLC where the product was eluted with an isocratic gradient of 94% Buffer A and 6% acetonitrile. Product fraction collection was initiated once the product peak was detected. Each fraction was analyzed and an acceptance criterion of greater than 80% AUC of the main peak was used for the initial product fractions. When fractions were combined, the level of impurities and relative concentrations of the pooled fractions were taken into account for selection criteria that met the final product specifications. To the product fractions, 10% aqueous sodium sulfite solution was added equal to 10% of the original volume of the collected fractions.

[0202] The following example represents the output of a single injection. Outputs of multiple injections may be tailored as well. A product fraction volume of 3.5 L (containing sodium sulfite) was collected and the pH was adjusted to 4.0-4.5 with sodium hydroxide solution. The aqueous solution was washed with 2 L of dichloromethane and the organic layer was separated and discarded.

[0203] The pH of the aqueous layer was adjusted to 7.5-8.5 with sodium hydroxide and the product was extracted four times with 2.4 L of dichloromethane. Before each extraction, the pH was adjusted again to 7.5-8.5 with sodium hydroxide or MSA.

[0204] The four dichloromethane layers were combined and concentrated to approximately 200 mL, which was slowly added (over approximately 10 min) to vigorously stirred n-heptane (2.5 L). The suspension was stirred at room temperature for approximately 10 min and gradually diluted (over 5 min) with 1.5 L of n-heptane. The slurry was cooled to 0-5° C. and stirred for 1-2 h. The suspended solid was filtered and washed with 3×150 mL of n-heptane. The product was dried under vacuum at 40° C. for at least 24 h until a constant weight was achieved and all residual solvent levels were within specifications. Approximately 13.6 g of 9-(2',2'-dimethylpropylaminomethyl)minocycline free base was isolated as a yellow solid.

[0205] Example 3: Preparation of the crystalline HCl salt of Compound 1 Compound 1 (13 g) was dissolved in acetone (300 mL), filtered, and the filter paper was further washed with acetone. The combined filtrate and washings were cooled to 5° C. A solution of concentrated HCl (3.9 mL) in acetone (79 mL) was slowly added to the combined filtrate and washings with vigorous stirring. The resulting slurry was stirred in an ice bath for 15 min and filtered.

[0206] The first solid crop was washed with cold acetone and pentane and dried under vacuum for 48 hours to give 13.7 g of a yellow amorphous solid. The flask with the saturated filtrate was covered with aluminum foil and allowed to stand for 2 weeks, during which time a single crystal was observed to grow. The crystals were collected by filtration and washed with hexane.

[0207] Example 4: Preparation of crystalline methanesulfonate salt of compound 1 A 25 mL three-neck flask was charged with 3 mL of isopropanol (IPA) under an inert nitrogen atmosphere. A slurry was prepared by adding 225 mg of amorphous free base of compound 1 to the flask. The slurry was warmed to a temperature of 45° C. Methanesulfonic acid hydrate (98.0 mg) was then added to the slurry. The slurry was stirred at 45° C. for 1 hour and then cooled to 22° C. to produce a thick crystalline slurry. The slurry was filtered and washed with IPA (2×1 mL). Excess IPA was removed from the crystal cake by drying at 55° C. for more than 2 hours to achieve a constant weight. The crystalline mesylate (methanesulfonic acid) salt of compound 1 (180 mg) was isolated. The crystalline mesylate salt was determined to be unstable at 5° C.

[0208] Example 5: Preparation of crystalline tosylate salt of Compound 1 (using the slurry method) A 5 L three-neck flask was charged with 2.0 L of isopropanol (IPA) under an inert nitrogen atmosphere. A slurry was prepared by adding 289 g of the amorphous free base of Compound 1 to the flask. A solution of p-toluenesulfonic acid hydrate (97.0 g) in IPA (400 mL) was added to the slurry. The water content of the slurry supernatant was adjusted to 0.6 g / L by adding water (9 mL) and the slurry was stirred at 20-25° C. for 18 hours to produce a thick crystalline slurry. The slurry was filtered and washed with IPA (2×500 mL). Excess IPA was removed from the crystal cake by blowing dry nitrogen through the cake for 24 hours. For solids containing 3 weight percent (wt%) IPA, the cake was further dried by blowing moist nitrogen through the cake at 70-75% relative humidity for 24 hours. The cake retained 0.9 wt% IPA, which was not further reduced by this method. Excess water was removed from the cake by blowing dry nitrogen through it for 24 hours. The tosylate salt of compound 1 was isolated as an orange powder (337 g). The isolated tosylate salt of compound 1 was crystalline with the only observed morphology: a nonstoichiometric hemihydrate as determined by X-ray powder diffraction (XPRD) and thermogravimetry (TG) analysis.

[0209] Example 6: Preparation of crystalline tosylate salt of compound 1 (using a solution method) A 5 L three-neck flask was charged with 1.7 L of methanol and 1.7 L of methyl-t-butyl ether under an inert nitrogen atmosphere. p-Toluenesulfonic acid monohydrate (209 g) and the amorphous free base of compound 1 (556 g) were added to the flask with stirring to obtain a clear solution. A seed amount of the monotosylate salt of compound 1 (3 g) was added to initiate crystallization, and additional amounts of methanol (0.1 L) and methyl-t-butyl ether (0.5 L) were added. The resulting slurry was stirred at about 20° C. for 22 hours to produce a thick crystalline slurry. The slurry was filtered and washed with a mixture of 1.1 L of methanol and 1.3 L of methyl-t-butyl ether, followed by methyl-t-butyl ether (2×2.4 L). The tosylate salt of compound 1 was isolated as an orange powder. Excess solvent was removed from the crystal cake by blowing dry nitrogen through the cake for 24 hours. The cake was then dried under vacuum at about 30° C. until the solid contained about 6 weight percent (wt%) of solvent. The cake was further dried under vacuum at about 45° C. until the solid contained less than 3 weight percent (wt%) of solvent. The isolated tosylate salt of Compound 1 was crystalline with the observed form 1 as determined by X-ray powder diffraction (XPRD).

[0210] Example 7: Characterization of the Tosylate Salt of Compound 1 The XRPD pattern of the isolated tosylate salt of compound 1 contained 2θ values ​​of 5.6, 8.0, 8.6, 11.4, 13.0, 15.5, 18.8, 20.4, and 24.5°.

[0211] The crystalline tosylate salt was subjected to thermogravimetry (TG) analysis at a heating rate of 10° C. / min under nitrogen flow. A weight loss of 3.9% was observed by 81.3° C., which was attributed to loss of water.

[0212] Upon drying, the water content of the crystalline tosylate salt of Compound 1 was calculated to be 0.5%. After standing at room temperature for 24 hours, this value increased to 5%. In contrast to amorphous Compound 1, the crystalline tosylate salt of Compound 1 was stable at room temperature for weeks and months, maintaining a water content of approximately 5%.

[0213] Hygroscopicity of the subject crystalline tosylate salts was determined using a symmetric vapor sorption analyzer and reported as weight % gained as a function of percent relative humidity (%RH) from 5% to 95% to 1% at 25° C. in 5% intervals at 25° C. A maximum weight gain of 12 wt % was observed at 95% RH with slight hysteresis upon desorption, and a loss of 2 wt % with IPA was observed.

[0214] The crystalline tosylate salts were determined to have solubilities summarized in Table 6 below. Solubility was determined by mixing an excess of solid with a solvent for 2 hours at ambient temperature followed by filtering the supernatant. The concentration of the supernatant was determined by high performance liquid chromatography (HPLC). Equilibration of 56.8 mg of the subject crystalline tosylate salt in 0.5 mL of water and 122.1 mg of the subject crystalline tosylate salt in 1.0 ml of water gave clear solutions. The pH of 122.1 mg of the subject crystalline tosylate salt in 1.0 mL of water was determined to be 5.70.

[0215] [Table 6]

[0216] Example 8: XRPD of Compound 1 X-ray powder diffraction patterns were collected on a Siemens D5000 diffractometer using Cu Kα radiation (40 kV, 40 mA) with a θ-θ goniometer, divergence V20 and receiving slits, a graphite secondary monochromator and a scintillation counter. The instrument performance was checked using a certified Corundum standard (NIST 1976). The software used for data collection was Diffrac Plus XRD Commander v2.3.1 and data were analyzed and displayed using Diffrac Plus EVA v 11,0.0.2 or v 13.0.0.2.

[0217] Powder samples were prepared using flat plate specimens. Approximately 35 mg of sample was gently packed into a cavity cut into a polished zero background (510) silicon wafer. The sample was rotated in its own plane during analysis. Data collection details are as follows: Angle range: 2~42°2θ Step size: 0.05° 2θ Acquisition time: 4 seconds / step High-resolution X-ray powder diffraction patterns were collected on a Bruker AXS C2 GADDS diffractometer using Cu Kα radiation (40 kV, 40 mA), an automated XYZ stage, a laser video microscope for automated sample positioning, and a HiStar 2D area detector. The X-ray optics consisted of a single Gobel multilayer mirror coupled to a 0.3 mm pinhole collimator.

[0218] The beam divergence, i.e., the effective size of the X-ray beam at the sample, was about 4 mm. Using the θ-θ continuous scan mode with a sample-detector distance of 20 cm, this gives an effective 2θ range of 3.2° to 29.7°. Typically, the sample would be exposed to the X-ray beam for 120 seconds. The software used for data collection was GADDS for WNT 4.1.16 and the data were analyzed and displayed using Diffrac Plus EVA v 9.0.0.2 or v 13.0.0.2.

[0219] Example 9: Temperature and Moisture Stability Test Stability studies were performed on the tosylate and mesylate salts of Compound 1 by monitoring the change in high performance liquid chromatography (HPLC) impurity profile for each salt upon exposure to various temperature and / or humidity conditions. Samples were placed in sealed containers and exposed to three controlled environments: refrigerated (5° C.), 20° C. and 60% relative humidity, and 40° C. and 75% relative humidity. After two weeks, the crystalline tosylate salt was determined to be the most stable crystalline form of Compound 1. Stability studies of the crystalline tosylate salt continued.

[0220] Samples were analyzed by the following reverse phase HPLC impurity profile method at 0, 1, 2, 4 weeks (Table 7) and 3 months (Table 8) for the tosylate salt; and at 0, 1, and 2 weeks (Table 9) for the mesylate salt.

[0221] Reverse-phase HPLC analysis was performed using a SYMMETRY SHIELD RP 18 column (4.6 x 250 mm, 5 pm particle size), although analyses using similar or equivalent columns would be expected to yield similar results. The mobile phase components were 0.01 M aqueous ammonium acetate at pH 3.3 (A) and acetonitrile (B). The mobile phase components were a gradient increasing from 6% to 15% B in 5 min, held at 15% B for 15 min, increasing from 15% to 60% B in 10 min, then increasing from 60% to 90% B in 2 min, after which the system was re-equilibrated at 6% B for 4 min. The flow rate was 1.0 mL / min and the injection volume was 10.0 μL. The column temperature was maintained at 30°C. Detection was by ultraviolet light (UV) at 280 nm. The retention time of compound 1 was approximately 15.7 min. The sample solution was prepared in mobile phase A to a final concentration of 2.0 mg / mL.

[0222] [Table 7] *RH refers to relative humidity. **Total impurities included all impurities in the specified batch. ***RRT 1.26 refers to the β-epimer.

[0223] [Table 8] *RH refers to relative humidity. **Total impurities included all impurities in the specified batch.

[0224] [Table 9]

[0225] The above data demonstrate that the tosylate salt of Compound 1 is stable when stored under refrigeration and / or 20°C & 60% RH conditions for at least 4 weeks. The tosylate salt of Compound 1 is stable at temperatures ranging from 0°C to 70°C, or from 5°C to 50°C, or from 20°C to 30°C.

[0226] Example 10: Photostability test A photostability study was performed on the tosylate salt of Compound 1. Two samples were prepared in clear glass Petri dishes. One sample was covered with aluminum foil to serve as a control. Both samples were placed in an ES 2000 Environmental Light 10 chamber and exposed to 12 klux cool white fluorescent light for a total of 47 hours. The samples were analyzed by the HPLC impurity profile method and the results are summarized in Table 10.

[0227] [Table 10]

[0228] equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.

[0229] All patents, patent applications, and literature references cited herein are expressly incorporated herein by reference.

Claims

[Claim 1] The invention described in the specification of this application.

Citation Information

Patent Citations

  • Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation

    US2980584A

  • Stable solutions of salts of tetracyclines for parenteral administration

    US2990331A

  • Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation

    US3062717A

  • 13-substituted-6-deoxytetracyclines and process utilizing the same

    US3165531A

  • Tetracycline antibiotic compositions for oral use

    US3454697A